Intelligent Bio Solutions Inc. entered into a securities purchase agreement with two healthcare-focused institutional investors for a private placement under Nasdaq rules, issuing 2,298,850 shares of common stock (or pre-funded warrants in lieu thereof) and warrants to purchase up to an additional 2,298,850 shares each of Series K-1 and Series K-2. Priced at $4.35 per unit, the transaction is expected to generate gross proceeds of approximately $10.0 million before placement agent fees and expenses. The Series K warrants carry an exercise price of $4.10 per share and a five-year term following effectiveness of the underlying registration statement. Closing is anticipated on or about January 2, 2026, with Ladenburg Thalmann & Co. Inc. serving as exclusive placement agent. Net proceeds will bolster working capital and general corporate purposes, providing additional runway as the Company advances commercial deployment of its rapid, non-invasive testing systems.

Intelligent Bio Solutions has forged a strategic collaboration with Syrma Johari MedTech Ltd. to scale production of its Intelligent Fingerprinting Drug Screening Reader. Under the agreement, Syrma Johari—operating 14 manufacturing sites and four design centers across India, Europe and the U.S.—will expand capacity to roughly four times the Company’s current output. Intelligent Bio anticipates annual production cost savings exceeding 40%, translating into a roughly 20 percentage-point improvement in gross margin versus its previous contract manufacturing arrangement. The partnership mitigates single-supplier exposure, enhances supply-chain resilience and positions the Company to meet surging global demand as it prepares for planned U.S. market entry in 2026. Syrma Johari’s new medical-grade plastics facility in India, scheduled to begin operations in January 2026, will further support this scale-up.